Mesoblast Management
Management criteria checks 4/4
Mesoblast's CEO is Silviu Itescu, appointed in Jan 2011, has a tenure of 13.33 years. total yearly compensation is $1.11M, comprised of 60.6% salary and 39.4% bonuses, including company stock and options. directly owns 6.92% of the company’s shares, worth $56.47M. The average tenure of the management team and the board of directors is 4.6 years and 5.9 years respectively.
Key information
Silviu Itescu
Chief executive officer
US$1.1m
Total compensation
CEO salary percentage | 60.6% |
CEO tenure | 13.3yrs |
CEO ownership | 6.9% |
Management average tenure | 4.6yrs |
Board average tenure | 5.9yrs |
Recent management updates
Recent updates
Mesoblast Limited: Back From The Dead
Apr 10Mesoblast GAAP EPS of -$0.14, revenue of $10.21M
Aug 31Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS
Apr 30Mesoblast issues FQ2 operational and financial update
Jan 29Mesoblast's rexlemestrocel-l reduces heart attacks, strokes
Jan 11Mesoblast: The Future Looks Bleak
Dec 24Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events
Dec 15Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%
Dec 02Mesoblast EPS beats by $0.22, misses on revenue
Nov 19CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$73m |
Sep 30 2023 | n/a | n/a | -US$81m |
Jun 30 2023 | US$1m | US$673k | -US$82m |
Mar 31 2023 | n/a | n/a | -US$81m |
Dec 31 2022 | n/a | n/a | -US$84m |
Sep 30 2022 | n/a | n/a | -US$86m |
Jun 30 2022 | US$1m | US$697k | -US$91m |
Mar 31 2022 | n/a | n/a | -US$92m |
Dec 31 2021 | n/a | n/a | -US$97m |
Sep 30 2021 | n/a | n/a | -US$97m |
Jun 30 2021 | US$2m | US$757k | -US$99m |
Mar 31 2021 | n/a | n/a | -US$109m |
Dec 31 2020 | n/a | n/a | -US$98m |
Sep 30 2020 | n/a | n/a | -US$97m |
Jun 30 2020 | US$2m | US$697k | -US$78m |
Mar 31 2020 | n/a | n/a | -US$66m |
Dec 31 2019 | n/a | n/a | -US$76m |
Sep 30 2019 | n/a | n/a | -US$76m |
Jun 30 2019 | US$1m | US$709k | -US$90m |
Mar 31 2019 | n/a | n/a | -US$90m |
Dec 31 2018 | n/a | n/a | -US$86m |
Sep 30 2018 | n/a | n/a | -US$48m |
Jun 30 2018 | US$2m | US$748k | -US$35m |
Mar 31 2018 | n/a | n/a | -US$42m |
Dec 31 2017 | n/a | n/a | -US$30m |
Sep 30 2017 | n/a | n/a | -US$64m |
Jun 30 2017 | US$1m | US$776k | -US$77m |
Compensation vs Market: Silviu's total compensation ($USD1.11M) is below average for companies of similar size in the US market ($USD3.42M).
Compensation vs Earnings: Silviu's compensation has been consistent with company performance over the past year.
CEO
Silviu Itescu (66 yo)
13.3yrs
Tenure
US$1,109,634
Compensation
Prof. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACRA, FTSE has been the Chief Executive Officer and Managing Director of Mesoblast Limited since 2011. Prof. Itescu is the Chief Executive Officer at Mesobla...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 13.3yrs | US$1.11m | 6.92% $ 56.5m | |
Chief Medical Officer & Executive Director | 2.3yrs | US$1.02m | no data | |
Interim Chief Finance Officer | 2.8yrs | no data | no data | |
General Counsel & Corporate Executive | 12.8yrs | no data | no data | |
Head of Spinal Orthopedic Disorders | 8.6yrs | no data | no data | |
Head of Pharma Partnering | no data | no data | no data | |
Head of Regulatory Affairs & Quality Management | no data | no data | no data | |
Head of Manufacturing | no data | no data | no data | |
Joint Company Secretary | 4.6yrs | no data | no data | |
Joint Company Secretary | 2.1yrs | no data | no data | |
Executive | no data | no data | no data |
4.6yrs
Average Tenure
66yo
Average Age
Experienced Management: MESO's management team is considered experienced (4.6 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 16.9yrs | US$1.11m | 6.92% $ 56.5m | |
Chief Medical Officer & Executive Director | 11.1yrs | US$1.02m | no data | |
Independent Non-Executive Director | 3.2yrs | US$135.62k | 0.022% $ 176.2k | |
Independent Non-Executive Chairman | 5.9yrs | US$247.95k | 0.040% $ 328.6k | |
Independent Non-Executive Vice Chairman | 10.2yrs | US$132.70k | 0.0093% $ 76.0k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Non-Executive Director | 1.8yrs | US$139.29k | 0.048% $ 388.7k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Non Executive Director | 2.2yrs | US$138.33k | 0.034% $ 277.1k |
5.9yrs
Average Tenure
71yo
Average Age
Experienced Board: MESO's board of directors are considered experienced (5.9 years average tenure).